Patients with blood cancers like polycythemia vera, a kind of myeloproliferative neoplasm, may benefit in learning more about ...

Dr. Raajit K. Rampal and Dr. Joshua K. Sabari walk through updates for patients in the treatment of blood cancers, including polycythemia vera.

More information: Islam E. Elkholi et al, Targeting the Dependence on PIK3C3-mTORC1 Signaling in Dormancy-Prone Breast Cancer Cells Blunts Metastasis Initiation, Cancer Research (2025). DOI: 10. ...

The cancer cells of some men feature a striking mutation: their Y chromosome is missing altogether. Now, tantalizing research suggests that this mutation can spread ‘contagiously’ from tumour ...

A study initiated by a University of Arizona Comprehensive Cancer Center physician-scientist defined for the first time how loss of the Y chromosome in male immune cells negatively affects immune ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer (SCLC). The DLL3xCD3 bispecific has shown that it can help patients live ...

A blood test analyzing cell-free DNA with whole-genome sequencing and machine learning demonstrated 87.4% sensitivity and 97.8% specificity for multi-cancer detection, correctly predicting tissue ...

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer.

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain cancer with few treatment ...

Background: BPDCN is a rare, clinically aggressive hematological malignancy primarily involving the skin, bone marrow, and lymph nodes. CD123 (IL-3Rα) is highly overexpressed on the surface of all ...

Outcomes in patients (pts) younger than 50 years old (yo) with treatment-naïve blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG): Subanalysis of a phase 1/2 trial.